NCT04555603View on ClinicalTrials.gov

Axitinib Therapy Management Study

WithdrawnOBSERVATIONAL

0

Timeline

Start Date

September 15, 2020

Primary Completion Date

February 22, 2021

Study Completion Date

February 22, 2021

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Inlyta

axitinib

DRUG

Bavencio

avelumab

DRUG

Keytruda

Pembrolizumab

Trial Locations (1)

10017

Pfizer Inc., New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT04555603 - Axitinib Therapy Management Study | Biotech Hunter | Biotech Hunter